Skip to main content
. 2016 Aug 26;2016(8):CD004131. doi: 10.1002/14651858.CD004131.pub3

Comparison 2. Acupuncture plus baseline treatment versus baseline treatment alone.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Improvement of dependency at the end of treatment 11   Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Barthel Index 9 616 Mean Difference (IV, Random, 95% CI) 9.19 [4.34, 14.05]
1.2 Modified Barthel Index 1 60 Mean Difference (IV, Random, 95% CI) 3.44 [0.30, 6.58]
1.3 ADL 1 62 Mean Difference (IV, Random, 95% CI) 7.80 [6.04, 9.56]
2 Improvement of dependency at the end of follow‐up 2   Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Barthel index 1 147 Mean Difference (IV, Random, 95% CI) 7.49 [1.79, 13.19]
2.2 ADL 1 71 Mean Difference (IV, Random, 95% CI) 3.83 [2.67, 4.99]
3 Improvement of global neurological deficit at the end of treatment 6   Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Modified Edinburgh and Scandinavian Stroke Scale 4 240 Mean Difference (IV, Random, 95% CI) ‐2.39 [‐3.34, ‐1.43]
3.2 Neurological function deficit scale 2 123 Mean Difference (IV, Random, 95% CI) ‐1.02 [‐5.80, 3.76]
4 Improvement of global neurological deficit at the end of follow‐up 2   Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Neurological function deficit scale 1 71 Mean Difference (IV, Random, 95% CI) ‐6.15 [‐7.09, ‐5.21]
4.2 NIHSS 1 147 Mean Difference (IV, Random, 95% CI) ‐0.83 [‐1.94, 0.28]
5 Improvement of global neurological deficit at the end of treatment 7 543 Odds Ratio (M‐H, Random, 95% CI) 3.89 [1.78, 8.49]
6 Improvement of motor function at the end of treatment 5   Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 Upper and lower extremities motor function(Fugl‐Meyer Assessment) 4 245 Mean Difference (IV, Fixed, 95% CI) 6.16 [4.20, 8.11]
6.2 General motor function (Motor assessment scale) 1 60 Mean Difference (IV, Fixed, 95% CI) 4.53 [2.99, 6.07]
7 Improvment of general motor function at the end of follow‐up (Fugl‐Meyer Assessment) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
8 Improvement of motor function at the end of treatment (Fugl‐Meyer Assessment) 2 125 Odds Ratio (M‐H, Random, 95% CI) 2.41 [0.98, 5.96]
9 Improvement of cognitive function at the end of treatment 5   Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 MMSE 5 278 Mean Difference (IV, Random, 95% CI) 2.54 [0.03, 5.05]
9.2 MoCA 2 120 Mean Difference (IV, Random, 95% CI) 1.34 [0.76, 1.92]
9.3 HDS‐R 1 46 Mean Difference (IV, Random, 95% CI) 1.26 [0.29, 2.23]
10 Improvment of cognitive function at the end of follow‐up (MMSE) 1 71 Mean Difference (IV, Fixed, 95% CI) 3.47 [2.43, 4.51]
11 Improvement of cognitive function at the end of treatment 3   Odds Ratio (M‐H, Random, 95% CI) Subtotals only
11.1 MMSE 3 166 Odds Ratio (M‐H, Random, 95% CI) 3.82 [1.89, 7.72]
11.2 HDS‐R 1 46 Odds Ratio (M‐H, Random, 95% CI) 4.02 [1.12, 14.46]
12 Improvement of depression at the end of treatment 6   Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 HAMD 6 552 Mean Difference (IV, Fixed, 95% CI) ‐2.58 [‐3.28, ‐1.87]
12.2 Symptoms of TCM depression scale 1 60 Mean Difference (IV, Fixed, 95% CI) ‐1.57 [‐2.96, ‐0.18]
13 Improvement of depression at the end of treatment (HAMD) 4 342 Odds Ratio (M‐H, Random, 95% CI) 2.03 [1.10, 3.72]
14 Improvement of swallowing function at the end of treatment (Water drinking test) 2 200 Mean Difference (IV, Random, 95% CI) ‐1.11 [‐2.08, ‐0.14]
15 Improvement of swallowing function at the end of treatment (Water drinking test) 1 60 Odds Ratio (M‐H, Random, 95% CI) 95.29 [10.93, 830.86]
16 Improvement of pain at the end of treatment (Visual Analogue Scale) 2 118 Mean Difference (IV, Fixed, 95% CI) ‐2.88 [‐3.68, ‐2.09]
17 Improvement of sleep quality at the end of treatment (Rhone Planck Sleepiness Scale) 1 60 Mean Difference (IV, Fixed, 95% CI) ‐1.09 [‐2.37, 0.19]
18 Improvement of spasticity at the end of treatment (Modified Ashworth Spasticity Rating Scale) 1 60 Mean Difference (IV, Fixed, 95% CI) ‐0.4 [‐0.64, ‐0.16]
19 Improvement of quality of life at the end of treatment (MOS SF‐36) 1 71 Mean Difference (IV, Fixed, 95% CI) 2.73 [‐0.54, 6.00]